Dimazon w/v solution for injection Data Sheet
Presentation
Dimazon 5% w/v Solution for Injection contains 50 mg/ml of Furosemide (as the monoethanolamine salt). The product also contains 0.234 mg/ml Miripirium Chloride, 1 mg/ml Disodium Edetate Dihydrate and 1.8 mg/ml Sodium sulphite anhydrous as antioxidants. It is a clear yellowish fluid.
Uses
As a potent saluretic type of diuretic for parenteral administration to cattle, horses, cats and dogs. It is indicated in the treatment of oedemata associated with cardiac insufficiency, renal dysfunction, trauma and parasitic disease. It is also recommended for the treatment of mammary oedema and limb oedemata. The product gives rapid onset of diuretic action with increased sodium and water excretion and is effective even in cases where glomerular filtration is impaired.
Dosage and administration
Species | Dosage mg active/kg bodyweight | ml of 5% solution | Administration |
Horse | 0.5-1.0 i.v. | 1-2 ml per 100kg | 1-2 times/day at intervals of 6-8 hours. |
Cattle | 0.5-1.0 i.v. | 1-2 ml per 100kg | At intervals of 12-14 hours. |
Dog/cat | 2.5-5.0 i.m./ i.v. | 0.25-0.5 (per 5kg bodyweight) | First dose 5mg/kg reduced to 1-2mg/kg for maintenance at 6-8 hours intervals. |
In severe or refractory cases the dose may be doubled on a single occasion in the horse or cow.
Dimazon 5% Solution may be administered by intramuscular injection in dogs and cats or intravenous injection for cattle, horses, dogs and cats, observing aseptic precautions.
The product can be used during pregnancy and lactation.
Contra-indications, warnings, etc.
The product is not indicated in cases of acute glomerular nephritis, renal failure with anuria, electrolyte deficiency disease or overdosage with digitalis.
Do not use in horses intended for human consumption.
Do not use concurrently with aminoglycoside antibiotic treatment.
Too rapid injection in dogs may cause staggering and vomiting.
The therapeutic effect may be impaired by increased intake of drinking water. So far as the patient's condition allows, the amount of drinking water should be restricted during treatment.
In pulmonary oedema of cardiac origin combined therapy with appropriate cardiac treatment is advisable. Only during prolonged treatment is it necessary to monitor potassium balance. Potassium supplements may be necessary.
Potential interactions with other drugs include ototoxicity with aminoglycosides and nephrotoxicity with cephalosporins.
Use in combination with sulphonamide treatment may lead to sulphonamide allergy.
Doses higher than recommended may cause transitory deafness.
Cardiovascular side effects may be observed in weak and old patients following overdosage.
Clinical experience with dogs indicates that improved results can frequently be achieved by supplementary administration of corticosteroids.
User Warnings
Care should be taken to avoid accidental self-injection. If irritation occurs, seek medical attention, showing the product label to a doctor. Following skin/eye contamination, wash/irrigate area with clean, running water immediately. Wash hands after use.
Withdrawal periods
Animals must not be slaughtered for human consumption during treatment. Cattle may be slaughtered for human consumption only after 28 days from last treatment.
Milk withdrawal period
24 hours.
Not to be used in horses intended for human consumption.
Treated horses may never be slaughtered for human consumption.
The horse must have been declared as not intended for human consumption under national horse passport legislation.
For animal treatment only. Keep out of the reach and sight of children.
Pharmaceutical precautions
Do not store above 25°C. Protect from light. If the product is stored for a prolonged period below +18°C, crystalline precipitation may occur. Do not use the product whilst the crystals are present. The crystals may be re-dissolved by shaking the vial and storing it for only 24 hours at 30°C - 40°C. Once the crystals are re-dissolved, the product may be used. Following withdrawal of the first dose use the product within 28 days. When the vial is broached for the first time, use the in-use shelf life which is specified on the packaging to calculate the date on which any remaining product should be discarded. This discard date should be written in the space provided on the label.
The product should not be mixed with other preparations.
Keep container in outer carton. Discard unused material.
Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.
Legal category
POM-V
Package quantities
10 ml multi-dose glass vials. Not all presentations may be marketed.
Further information
Nil.
Marketing authorisation number
Vm 01708/4406.
Date of text preparation:
May 2011
